nature research

Corresponding author(s):	Velibor Misic
Last updated by author(s):	Nov 11, 2020

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

_				
C-	ta:	tic	+i	~
_	_			·

Fora	all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	Confirmed			
	The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
\boxtimes	A stateme	nt on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.			
\boxtimes	A description of all covariates tested			
\boxtimes	A descript	ion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)			
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.			
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings			
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
\boxtimes	\boxtimes Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated			
,		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
Software and code				
Polic	cy information a	about <u>availability of computer code</u>		
Da	ata collection	No software was used for data collection.		
Da	ata analysis	All data analysis was performed in the R and Julia programming languages. The Julia code for our simulation method and an example of how it		

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

is used can be found at the following repository: http://github.com/vvmisic/finsim-code/

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The datasets generated during and/or analyzed during the current study are not publicly available due to institutional restrictions on data sharing and privacy concerns. However, the data are available from the authors on reasonable request.

Field-specific reporting			
Please select the one below	w that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
Life sciences	Behavioural & social sciences		
For a reference copy of the docum	ent with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Behavioural	& social sciences study design		
All studies must disclose or	n these points even when the disclosure is negative.		
Study description	This is a retrospective study using quantitative data on surgical patients at the UCLA Ronald Reagan Medical Center.		
Research sample	The sample consists of records of surgical patients admitted at the UCLA Ronald Reagan Medical Center in the period 2017-2018.		
Sampling strategy	There was no sampling involved; all of the patient data in the period 2017-2018 was used to test our methodology.		
Data collection	The data used was extracted from the Perioperative Data Warehouse (PDW), an electronic health record system in use at UCLA		
Timing	The data was extracted from 2017-2018.		
Data exclusions	Out of 19343 admissions in the period 2017-2018, 12 were excluded for being organ donors (see paper for details).		
Non-participation	No participants dropped out/declined participation. (No live participants were used; our entire study is based on retrospective/historical data.)		
Randomization	There is no treatment being tested, so there was no randomization performed to assign subjects to different treatment groups.		
	or specific materials, systems and methods authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,		
	evant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & experime			
n/a Involved in the study Antibodies			
Antibodies Like Li	ChIP-seq		
Palaeontology and a			
Animals and other o	organisms		
Human research participants			
Clinical data			
Dual use research o	f concern		
Human research participants			
Policy information about studies involving human research participants			
Population characteristic	See above.		
Recruitment	N/A		
Ethics oversight	thics oversight Ethics approval was obtained from UCLA (UCLA IRB #18-000630).		
Note that full information on the approval of the study protocol must also be provided in the manuscript.			
ChIP-seq			
Data deposition			

Confirm that both raw and final processed data have been deposited in a public database such as <u>GEO</u>.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication.

For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

Files in database submission

Provide a list of all files available in the database submission.

Genome browser session (e.g. UCSC)

Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

Methodology

Antibodies

Replicates Describe the experimental replicates, specifying number, type and replicate agreement.

Sequencing depth

Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.

Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot

number.

Peak calling parameters | Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files

usea

Data quality Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.

Software

Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

Flow Cytometry

Plots

Confirm that:	
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).	
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical	markers).
All plots are contour plots with outliers or pseudocolor plots.	
A numerical value for number of cells or percentage (with statistics) is provided.	

Methodology

Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.

Instrument

Identify the instrument used for data collection, specifying make and model number.

Software

Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.

Cell population abundance

Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.

Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Experimental design

Gating strategy

Design type Indicate task or resting state; event-related or block design.

Design specifications

Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.

Behavioral performance measures

State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

Acquisition				
Imaging type(s)	Specify: functional, structural, diffusion, perfusion.			
Field strength Specify in		n Tesla		
1 0 01		he pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, kness, orientation and TE/TR/flip angle.		
Area of acquisition	State wh	ether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.		
Diffusion MRI Used	Not	used		
Preprocessing				
Preprocessing software	Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).			
Normalization	If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used f transformation OR indicate that data were not normalized and explain rationale for lack of normalization.			
Normalization template	Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.			
Noise and artifact removal	Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).			
Volume censoring	Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.			
Statistical modeling & inference				
Model type and settings	Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).			
Effect(s) tested	Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.			
Specify type of analysis: W	hole brain	ROI-based Both		
Statistic type for inference (See Eklund et al. 2016)	Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.			
Correction	Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).			
Models & analysis				
	a compostivity			
Functional and/or effective connectivity				
Graph analysis Multivariate modeling or predictive analysis				
Functional and/or effective conn	nectivity Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).			
		Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency,		

etc.).

Multivariate modeling and predictive analysis

Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.